Skip to main content
OTCMKTS:MBVXQ

MabVax Therapeutics Stock Forecast, Price & News

$0.02
+0.00 (+9.52 %)
(As of 03/19/2020)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.02
52-Week Range
$0.00
$0.30
Volume1,300 shs
Average Volume17,571 shs
Market Capitalization$212,865.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MBVXQ News and Ratings via Email

Sign-up to receive the latest news and ratings for MabVax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About MabVax Therapeutics

MabVax Therapeutics Holdings, Inc. is a clinical-stage drug development company. It is focused on discovering and developing small molecule drugs to treat cancer. TELINTRA is the Company's lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. MabVax Therapeutics Holdings, Inc., formerly known as Telik, Inc., is based in San Diego, California.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MBVXQ
CUSIPN/A
CIKN/A
Phone858-259-9405
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap$212,865.00
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1957th out of 2,045 stocks

Pharmaceutical Preparations Industry

757th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MabVax Therapeutics (OTCMKTS:MBVXQ) Frequently Asked Questions

What stocks does MarketBeat like better than MabVax Therapeutics?

Wall Street analysts have given MabVax Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MabVax Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of MabVax Therapeutics' key competitors?

What is MabVax Therapeutics' stock symbol?

MabVax Therapeutics trades on the OTCMKTS under the ticker symbol "MBVXQ."

How do I buy shares of MabVax Therapeutics?

Shares of MBVXQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MabVax Therapeutics' stock price today?

One share of MBVXQ stock can currently be purchased for approximately $0.02.

How much money does MabVax Therapeutics make?

MabVax Therapeutics has a market capitalization of $212,865.00.

What is MabVax Therapeutics' official website?

The official website for MabVax Therapeutics is www.mabvax.com.

Where are MabVax Therapeutics' headquarters?

MabVax Therapeutics is headquartered at 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121.

How can I contact MabVax Therapeutics?

MabVax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]


This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.